NCT04463420 is a NA clinical trial of PHR160 Spray in COVID-19, sponsored by Baqiyatallah Medical Sciences University.

Who is sponsoring NCT04463420?

NCT04463420 is sponsored by Baqiyatallah Medical Sciences University.

What drugs are being tested in NCT04463420?

Interventions in NCT04463420: PHR160 Spray, Placebo, Standard treatment.

Is NCT04463420 still recruiting?

NCT04463420 is currently status unknown. Last updated 4 November 2020.

Last reviewed 2020-11-04 · How we verify

NCT04463420

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Efficacy of PHR 160 Spray on the Outcomes of Patients With COVID-19

Status unknown NA Last updated 4 November 2020

What this trial tests

NA trial testing PHR160 Spray in COVID-19 in 224 participants. Status unknown.

Timeline

15 August 2020

Primary endpoint
15 November 2020

15 December 2020

Quick facts

Lead sponsor	Baqiyatallah Medical Sciences University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	224
Start date	15 August 2020
Primary completion	15 November 2020
Estimated completion	15 December 2020
Sites	1 location across Iran

Drugs / interventions tested

PHR160 Spray — full drug profile →
Placebo
Standard treatment

Conditions studied

COVID-19 — all drugs for COVID-19 →

Sponsor

Baqiyatallah Medical Sciences University

Who can join

Adults 18 to 75, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a multi-center randomized, controlled, and blinded clinical trial study that will be performed in four medical-educational centers. In this study, the samples will be selected from among patients with SARS-CoV-2 as easy access and based on entry criteria and will be randomly divided into two groups, including a control group and an intervention group. The study will be conducted in four medical centers. From each center, 56 definitive Corona patients will be selected, who will be randomly divided into two groups of 28, for a total of 224 patients will enter the study. In the intervention group, in addition to receiving the test spray, Patients will also receive standard treatment

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus.
Oliver JC, Silva EN, Soares LM, Scodeler GC, et al · · 2022 · cited 10× · PMID 36578829 · DOI 10.1177/25151355221144845

Verify or expand the search:

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other Baqiyatallah Medical Sciences University trials

Trials by the same sponsor.

NCT06369688 — IDEAL SKIIN CARES Bundle to Prevent Pressure Injury · NA · not yet recruiting
NCT04466280 — Efficacy and Safety of Mucoadhesive Sustained Release, Mucodentol, in Comparison With Hydroxychloroquine to Prevent COVI · NA · withdrawn
NCT04460092 — Using 32 - Gauge Needles With Lengths of 5 mm and 8 mm on Pain Post-injection, Leak and Blood Glucose · NA · unknown
NCT04376814 — Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19 · NA · completed
NCT04134403 — Steroids, Thiamine and Ascorbic Acid in Septic Shock · Phase 3 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04463420 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Baqiyatallah Medical Sciences University
Last refreshed: 4 November 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04463420.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing